CARB-BC predicted grade 3 to 5 adverse events, dose modifications, and hospitalizations.
CTC count may help guide the decision between first-line chemotherapy or endocrine therapy in ER-positive, HER-negative metastatic breast cancer.
A meta-analysis showed that breast cancer patients who have a pathologic complete response after neoadjuvant chemotherapy may not benefit from adjuvant chemotherapy.
Women and men were found to react differently to treatment with chemotherapy, although gender-based survival differences were not observed.
Research is still needed to explore the association between cancer chemotherapeutics and rheumatoid arthritis.
In a recent analysis of VA hospital records, more than half of all oncologic errors and adverse events were attributed to uncoordinated cancer care.
The addition of preoperative chemotherapy may eradicate micrometastatic disease and direct postoperative therapy in the case of resistance.
After the initial year of follow-up, 2 patients in the standard arm and 1 patient in the re-curettage arm had relapsed.
While checks were documented thoroughly in 3 centers, there were no internal standards for physician checks.
Metronomic Chemotherapy May Improve Outcomes Among Elderly Patients With HER2-Positive Breast CancerFebruary 12, 2018
Researchers evaluated whether dual HER2 inhibition with trastuzumab and pertuzumab plus metronomic cyclophosphamide is superior to dual HER2 inhibition alone.
DS-8201 is an investigational HER2-targeting ADC, a targeted therapy for cancer that delivers cytotoxic chemotherapy by means of a linker on the monoclonal antibody that attaches to a specific target on cancer cells.
Patients with triple-negative breast cancer without BRCA1 and BRCA2 germline mutations may benefit from the addition of carboplatin to a chemotherapy regimen.
Adding evofosfamide to doxorubicin is not recommended as a first-line treatment for patients with advanced soft-tissue sarcoma.
Once-daily radiotherapy is not superior to twice-daily treatment for patients with small-cell lung cancer receiving concurrent chemoradiotherapy.
Among patients suffering post-radiation or chemoradiation locoregional HNSCC recurrence, those with HPV-positive disease may have better survival rates.
A standard chemotherapy regimen was more efficacious than histotype-guided chemotherapy among patients with high-risk, localized sarcoma of the extremities or trunk wall.
A review of treatment options for patients experiencing chemotherapy- cr radiation-induced nausea and vomiting.
Many patients who receive chemotherapy or radiotherapy as a part of their treatment for cancer develop oral mucositis, which is a painful, debilitating condition.
Patients who reported better clinician communication or an improved satisfaction with their treatment were more likely to be adherent.
This study indicates that there is no difference in efficacy or safety between aprepitant and fosaprepitant, though the study was limited by its small sample size.
Study authors conclude that FLOT should be an internationally standard option for patients with resectable gastric cancer.
Adding ramucirumab to mFOLFOX6 therapy in an intent-to-treat population of patients with GEJ does not improve PFS.
Dopamine antagonist olanzapine prevents nausea and the complete response rate among previously untreated patients receiving highly emetogenic chemotherapy.
TAS-102 improved survival, when contrasted with placebo, for patients with refractory colorectal cancer, though the drug showed no activity for the second-line treatment of patients with small cell lung cancer.
Neratinib demonstrated clinical efficacy for patients with HER2-positive, hormone-receptor-negative breast cancer, in a phase 2 study.
Males with breast cancer are less likely to survive than females after disease recurrence, which may be due to less aggressive treatment after relapse.
Carfilzomib is superior to bortezomib for progression-free survival, regardless of previous treatments or prior exposure to either bortezomib or lenalidomide, for patients with multiple myeloma.
The combination of ixazomib, cyclophosphamide, and dexamethasone induced high response rates with good tolerability in patients with newly-diagnosed multiple myeloma.
Adjuvant chemotherapy with S-1 may improve standard of care for Japanese patients with resected pancreatic cancer.
Addition of olaratumab to doxorubicin significantly improves PFS and OS in patients with advanced soft-tissue sarcoma.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- CAR-T Trial for Triple-Negative Breast Cancer Under Way
- Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Phase 3 GEICAM/CIBOMA Results: Adjuvant Capecitabine in Triple-Negative Breast Cancer
- Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
- Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma
- Younger Breast Cancer Patients at Higher Risk for Osteoporosis
- Molecular Mechanisms Underlying Immunosurveillance in Multiple Myeloma Identified
- Gly101Val Mutation Directly Causes Resistance to Venetoclax
- Can Treatments for Childhood ALL Alter the Gut Microbiome?